Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference
Rhea-AI Summary
Bionano Genomics (Nasdaq: BNGO) announced that CEO Erik Holmlin, PhD, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. The presentation is scheduled for 3:00 p.m. to 3:25 p.m. ET.
Investors can access the presentation through a webcast, and a replay will be available on the company's investor relations website for at least 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – BNGO
In the Aug 6 session, BNGO declined 1.64%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025.
Conference & Webcast Details
| Date: | August 13, 2025 |
| Time: | 3:00 p.m. to 3:25 p.m. ET |
| Presenter: | Erik Holmlin, PhD, CEO of Bionano |
| Webcast: | Link to Register |
A replay / recording of the session will be available following the conference through the Bionano website at https://ir.bionano.com/ for at least 30 days.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com
